Methods: A longitudinal, multicenter, prospective natural history study enrolled 26 SMA infants and 27 control infants aged <6 months. Recruitment occurred at 14 centers over 21 months within the NINDS-sponsored NeuroNEXT (National Network for Excellence in Neuroscience Clinical Trials) Network. Infant motor function scales (Test of Infant Motor Performance Screening Items [TIMPSI] , The Children's Hospital of Philadelphia Infant Test for Neuromuscular Disorders, and Alberta Infant Motor Score) and putative physiological and molecular biomarkers were assessed preceding age 6 months and at 6, 9, 12, 18, and 24 months with progression, correlations between motor function and biomarkers, and hazard ratios analyzed. Results: Motor function scores (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in all healthy infants rapidly increased. Correlations were identified between TIMPSI and CMAP in SMA infants. TIMPSI at first study visit was associated with risk of combined endpoint of death or permanent invasive ventilation in SMA infants. Post-hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval, 6, 17) . Interpretation: These data of SMA and control outcome measures delineates meaningful change in clinical trials in infantile-onset SMA. The power and utility of NeuroNEXT to provide "real-world," prospective natural history data sets to accelerate public and private drug development programs for rare disease is demonstrated. ANN NEUROL 2017; 82:883-891 S pinal muscular atrophy (SMA) is the leading genetic cause of infant death with an incidence of 1 in 11,000 live births. 1, 2 Infantile-onset or type 1 SMA is characterized by muscle weakness, respiratory insufficiency, and premature death. 3, 4 SMA is a recessive disorder caused by deletion or mutation in the SMN1 (survival motor neuron 1) gene and retention of one or more copies of a nearly identical gene, SMN2 (survival motor neuron 2), which results in reduced expression of full-length SMN protein. 5, 6 SMN2 differs from SMN1 by a nucleotide substitution that results in exclusion of exon 7 in approximately 90% of transcripts. 7, 8 The messenger RNA (mRNA) that results, SMND7, produces a nonfunctional truncated protein targeted for degradation. 9,10 SMN2 copy number correlates inversely with clinical severity in humans and motor function and survival in murine models. [11] [12] [13] [14] An understanding of the molecular genetics, and the ability to produce faithful SMA animal models, has led to the development of small-molecule, therapeutic antisense oligonucleotides (ASOs) and gene replacement therapies. 15 More recently, SMA infants with 2 copies of SMN2 and symptom onset preceding 6 months were shown to have poor motor function and significant motor unit loss electrophysiologically, with a median age of death (or at least 16 hours/day required noninvasive ventilation) at age 10.5 months. 22 In a retrospective study, no SMA type 1 infants achieved major motor milestones such as rolling over or sitting independently. 23 A critical challenge for the use of natural history data in infantile-onset SMA is that data are often wholly or partially retrospective, are collected at one or a few specialty academic sites in a nonsystematic fashion, and have no comparison control group. The National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) SMA Infant biomarker Study was initiated in 2012 to describe and prospectively compare the natural history of motor function assessments during the first 2 years of life in SMA and healthy infants enrolled before age 6 months and to model the design of interventional studies in infantileonset SMA. 24 In addition to creating novel data sets, a primary goal was to examine correlations between candidate physiological and molecular biomarkers with motor function scores to inform the use of these measures in future clinical trials and clinical management.
Patients and Methods

Study Design and Participants
This was a prospective, multicenter, longitudinal natural history study in SMA and healthy infants designed to mimic a clinical trial. Fourteen sites in the United States participated. The protocol, patient demographics, and baseline characteristics were published previously. 24 Enrollment was restricted to infants who were aged 6 months and were born between 36 and 42 weeks' gestation. The study was performed and supported by the NeuroNEXT Clinical Trial Network and originated from The Ohio State University Wexner Medical Center (Supplementary Table S1 ). 25, 26 Parents or guardians of all participants provided written, informed consent approved by the Neuro-NEXT central institutional review board 27 at each site.
SMA was confirmed by genetic testing preceding enrollment. Asymptomatic participants genetically diagnosed before enrollment were included. Participants were excluded if they required noninvasive ventilatory support for >12 hours/day, had a comorbid illness, were on therapies thought to increase SMN expression, or were enrolled in a therapeutic trial. SMN1 gene deletion/mutation was excluded for the control infants, with confirmation of the SMN1 exon 7 deletion and SMN2 copy number performed as previously described. 28 Exclusion of the SMN2 gene-modifier mutation, c.859G>C, 29, 30 was confirmed.
Procedures
A description of the procedures has been published. 24 
Statistical Analysis
Mixed-effects models were used to compare outcome variables between SMA and control participants longitudinally. 37 For a given outcome variable, the model included terms for disease status, study visit, and the interaction between these two effects. The Akaike information criteria was applied to determine the most appropriate covariance structure. No adjustments were made for site-specific effects because of the small sample size. Because of the prognosis of SMA, it was expected that not all participants would survive until final follow-up. In these cases, all available data were used in the models. Study visit was modeled as a categorical variable to allow for possible nonlinear trends over time and the interaction between study visit and disease status was retained in the model if the p value associated with this effect was less than 0.20. Unless otherwise noted, a significance level of 0.05 was used to determine statistical significance. Correlation between motor function scores and putative biomarkers were assessed separately for SMA and control participants. To assess the correlation between motor function scores and biomarkers, a linear mixed-effects model approach was used. In these analyses, motor function scores were modeled longitudinally across study visit as a function of the biomarker corresponding to the same study visit. Correlation for these analyses was defined as the mean change in motor function score given a 1-unit increase in the biomarker. The parameter estimate associated with the biomarker indicates the direction and magnitude of the association.
The survival function for time to death or intubation was estimated using the Kaplan-Meier method. Participants who did not die or require intubation were considered to be censored events. Cox proportional regression models were used to estimate the hazard ratio (HR) for time to death or intubation as a function of motor function scores and biomarkers.
Results
Between December 14, 2012 and September 10, 2014, 26 SMA and 27 healthy infants were enrolled. The two cohorts were well matched for age, sex, and birth weight and height; detailed description of the baseline characteristics was published in 2016. 24 The last study visit occurred in August 2015. Twenty-three healthy infants (85.2%) completed the study. Two healthy infants (7.4%) discontinued because parents moved from a study site, and 2 were lost to follow-up. Seven SMA infants (26.9%) completed the study. There were 12 deaths (46.2%) in the SMA cohort, and 7 infants (26.9%) withdrew from the study before the 24-month visit (Fig 1) . Two infants received invasive ventilatory support during the study at ages 5 and 18 months; both survived to the 24-month visit.
In the SMA cohort, 16 infants had 2 copies of SMN2, 5 had 3 copies, and a single infant had 4 copies. 24 SMN2 copy number was not determined in 4
SMA infants because of insufficient blood samples. These 4 participants were imputed to have 2 copies of SMN2 based upon their baseline scores 24 and were included in that subgroup for analysis. SMN2 copy number was inversely associated with risk of death or permanent and future trials, the SMA cohort was studied as a whole (primary analysis) and as a subgroup where SMN2 5 2 or was unknown, excluding participants where SMN2 >2 (secondary analysis).
Weight Gain and Nutritional Support
Control infants gained more weight than SMA infants over the first 2 years of life; at 6 months, control participants were approximately 0.95kg heavier than SMA participants, and by the 24-month visit, they were 2.27kg heavier (Fig 2A; Supplementary Table S2) . Nine of the 20 SMA infants excluding participants with SMN2 >2 received nutrition by gastrostomy tubes while enrolled.
Motor Function
At enrollment, SMA infant TIMPSI scores were significantly lower than controls. 24 This difference increased with time (Supplementary Table S3 ). TIMPSI decreased in the SMA cohort excluding SMN2 >2 participants and rapidly increased in the control cohort (Fig 2B) . TIMPSI plateaued to a mean score of nearly 90 in the control cohort by the 6-month visit, whereas the mean TIMPSI in this SMA cohort, excluding SMN2 >2 participants, steadily declined to a score of 7 (standard deviation [SD], 6.56; n 5 3) by the 24-month visit. TIMPSI scores in SMA infants where SMN2 >2 increased initially (Fig 2B) . CHOP-INTEND scores in the SMA cohort were also significantly lower than in controls at enrollment. 24 All healthy controls reached a TIMPSI of greater than 41 after the 3-month visit and were thereafter not evaluated by CHOP-INTEND. Similarly, no SMA participants with SMN2 >2 were evaluated by the CHOP-INTEND after the 3-month visit. In the SMA cohort excluding SMN2 >2 participants, there was a decrease in the CHOP-INTEND (Fig 2C; Supplementary Table S4 ). The highest CHOP-INTEND score in the SMA cohort excluding SMN2 >2 participants was 33 for 1 infant at the 6-month visit. When analyzed by calculating the difference in scores from the 6-month visit, progression decline occurred through the first 12 months and then plateaued (Fig 3; Table 1 ).
The AIMS test was used for infants who had a TIMPSI 41 to account for infants whose motor function would "max out" on the TIMPSI. As a result, all control infants and only SMA infants where SMN2 >2 had the AIMS performed after the 3-month visit.
Performance increased for the first 9 months and then plateaued; control infant scores were higher than the SMN2 >2 infants (Fig 2D; Supplementary Table S5 ).
Progression of Candidate Biomarkers
CMAP amplitude and area were stable in control infants (Fig 2E; Supplementary Tables S6 and S7 ). The peak amplitude was 6.00mV (SD 5 2.14; n 5 26) at the 6-month visit and 6.87mV (SD 5 2.02; n 5 21) at the 24-month visit. The peak area was 11.28mV/s (SD 5 4.52; n 5 26) at the 6-month visit and 14.61mV/s (SD 5 4.11; n 5 21) at the 24-month visit. CMAP amplitude and area rapidly fell and were lower in the SMA cohort excluding SMN2 >2 participants than in controls at all time points and were often not detectable (Fig 2E; Supplementary Tables S6 and S7). CMAP amplitude was never higher than 0.6mV in SMA infants excluding SMN2 >2 participants aged 6 months.
SMN mRNA and protein levels from peripheral blood were stable over the first 2 years of life in healthy controls (6- Tables S8 and S9 ). 
Time to Combined Endpoint
The combined survival endpoint was defined as age at death or permanent ventilatory support. This endpoint has been used in clinical trials in infantile-onset SMA.
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The median survival time for SMA infants excluding SMN2 >2 participants was 8 months (95% CI, 6, 17; n 5 20; Fig 2F) . The median survival time for the SMA infants with >2 SMN2 copies was not reached, with 85% living at the 24-month end-of-study time point.
Correlations Between Motor Function and Candidate Biomarkers
Weight correlated negatively with the CHOP-INTEND in the SMA cohort, and when participants with SMN2 >2 were excluded from analysis, weight correlated negatively with the CHOP-INTEND and TIMPSI (Supplementary Table S10 ). CMAP peak amplitude and area correlated positively with the TIMPSI in the SMA cohort and in the SMA cohort excluding SMN2 >2 participants. The magnitude of this correlation varied by study visit in the SMA cohort; however, it was constant in the SMA cohort excluding SMN2 >2 participants (Supplementary Table S10 ). CMAP peak area had a positive correlation with the CHOP-INTEND at the 6-month visit, but at no other visits in the SMA cohort, and CMAP peak amplitude was not correlated with CHOP-INTEND in the SMA cohort or the SMA cohort excluding SMN2 >2 participants (Supplementary  Table S10 ). There were no correlations between motor function (TIMPSI or CHOP-INTEND) and SMN mRNA or protein levels in the SMA cohort excluding SMN2 >2 participants; however, SMN mRNA levels correlated positively with the TIMPSI score in the total SMA cohort at the 12-and 18-month visits and in the healthy cohort at all study visits (Supplementary Table S10 ).
Association of Biomarkers With Risk of Combined Endpoint
HRs were calculated to determine whether an outcome measure obtained at the first study visit predicted the time to combined endpoint in the SMA cohort (Table 2 ). Initial TIMPSI score was inversely associated with risk of combined endpoint (HR, 0.53; 95% CI, 0.30, 0.93), and this association was lost when participants with SMN2 >2 were excluded from the analysis. Initial weight, CHOP-INTEND score, and CMAP were not significantly associated with risk of combined endpoint in the total SMA cohort. HRs were not calculated for the SMN mRNA and protein levels because the collection of blood samples did not occur regularly in the SMA cohort and often were not collected until 12 months after enrollment. Thus, the potential bias associated with the fact that blood samples were more likely collected from healthier infants made it an unfair comparison to determine the HRs for SMN mRNA and protein levels.
Discussion
This study has generated definitive controlled data on the natural history of infantile-onset SMA. With the advent of effective disease-modifying therapies, 18 it is likely not ethical or feasible to perform future clinical trials that have a placebo arm. Thus, our data sets are critical for future investigation of improved therapies. The control infant data obtained here are also novel, contribute to our understanding of postnatal neuromuscular development, and provide a first benchmark to indicate full recovery in SMA trials and optimal clinical management. SMA infants rapidly lost motor function and CMAP responses within age 6 months and continued to lose function over the first 2 years of life. The median survival time in the SMA cohort excluding participants with >2 SMN2 copies of 8 months, determined in a multicenter study that best mimics the design of This is consistent with our results despite the different respiratory endpoint. Indeed, it is possible that the median survival in our cohort would have been even earlier had we used the same respiratory endpoint. Of note is that the standard of care and the timing of the initiation of hospice care in a nontreatment trial may differ from that in a clinical trial. Nevertheless, the rapid divergence of motor function and CMAP in SMA and control infants, manifest as early as age 6 months, suggests that this bias was not a major influence on median time to combined endpoint. Moreover, because there appears to be an early, nonlinear reduction of motor function by CHOP-INTEND, the data add urgency to the need for the inclusion of SMA genetic testing on newborn screening panels and for early therapeutic intervention. Meaningful biomarkers for SMA would shorten clinical trial timelines, reduce sample sizes, and predict treatment response. 38 35 and suggests that SMN blood levels may be useful as a pharmacodynamic biomarker for systemic SMN-targeted interventions. Correlations between SMN mRNA levels and TIMPSI in the control cohort may suggest that SMN expression is a positive modifier for motor function in healthy individuals that warrants further study. We successfully recruited and retained SMA and healthy control infants using 14 clinical sites geographically distributed across the United States. The ability to enroll and retain participants in this vulnerable, rare pediatric population illustrates the utility and power of the clinical trial infrastructure of the NeuroNEXT Clinical Trial Network. Moreover, the public data sharing from this study has been, and will continue to be, useful for drug development efforts, illustrating successful public investment in science that delineates meaningful outcomes for public health.
Considerations for effective clinical trial design in infantile-onset SMA can be gleaned from this study and recent clinical trials. With the FDA's approval of nusinersen, all future trails will involve infants receiving a disease-modifying medication. One must define the molecular genetics for each infant, including potential genetic modifiers, and ensure a stratification plan based on SMN2 copy number. Ensuring that baseline values for motor milestones, MFS, respiratory status, and CMAP are well matched between cohorts will also be crucial, as will pretreatment measurements of potential predictive biomarkers with particular attention to electrophysiological outcomes. Future clinical trial design should also include the longitudinal collection of blood, possibly cerebrospinal fluid samples, and electrophysiological outcomes to anticipate the need to predict how treated infants will fare throughout their lifetimes. With these recommendations, the optimization of future successful therapies for infantile-onset SMA will move forward with even greater alacrity.
